MedTrace Logo

A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients

NCT00799539 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2015-12-02

No results posted yet for this study

Summary

The primary reason for this study is to further assess safety and efficacy data of the bortezomib/melphalan/prednisone (BMP) regimen in previously untreated and transplant ineligible multiple myeloma patients

Conditions

Interventions

DRUG

bortezomib

From cycles 1-4, 1.3mg/m\^2 on days 1,4,8,11,22,25,29,and 32 of each 6-week cycle

DRUG

bortezomib

From cycles 5-9, 1.3mg/m\^2 on days 1, 8, 22, and 29 of each 6-week cycle

DRUG

melphalan

9 mg/m\^2 once daily on days 1-4 of each 6-week cycle

DRUG

prednisone

60 mg/m\^2 once daily on days 1-4 of each 6-week cycle

Sponsors & Collaborators

  • Ortho Biotech Canada

    collaborator UNKNOWN

  • Janssen-Ortho Inc., Canada

    lead INDUSTRY

Principal Investigators

  • Janssen-Ortho Inc. Clinical Trial · Janssen-Ortho Inc., Canada

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00799539 on ClinicalTrials.gov